In this episode, Martin discusses why he has become more cautious on SanDisk and explains the factors shaping his outlook for the company. He also reviews Jazz Pharmaceuticals, examines Sun Pharmaceutical Industries and Samsung Biologics, and analyzes Kioxia, sharing his perspective on each company's business, competitive position, valuation, and potential opportunities and risks.

In this episode, Martin discusses recent developments involving Capricor Therapeutics and shares his perspective on the company's disclosures and outlook. He also revisits his bearish thesis on AMD, analyzes Tyra Biosciences, explains why he is constructive on Sarepta, and discusses TENX, examining each company's business, valuation, competitive position, and the factors he believes could influence their future performance.

In this archive lesson, Martin discusses investing and financial analysis, explaining key concepts related to evaluating businesses, interpreting market behavior, and making investment decisions. He shares his perspective on valuation, risk management, and portfolio strategy while answering questions and illustrating the reasoning behind his approach to investing.

In this archive clip, Martin debates an 18-year-old participant about the pharmaceutical price increase that brought him widespread public attention. The discussion explores the reasoning behind the pricing decision, differing views on drug pricing and healthcare economics, and the ethical and business arguments raised by both sides during the exchange.

In this episode, Martin discusses Capricor Therapeutics and shares his perspective on the company's patient data and related public statements. He examines the clinical results, trial design, and regulatory considerations, explaining the factors that shape his investment outlook and why he questions aspects of the company's interpretation of the data.

In this episode, Martin discusses the investing approach of Steve Cohen and the characteristics he believes contribute to long-term trading success. He also shares his perspective on managing drawdowns, controlling risk during periods of underperformance, and developing exit strategies for short positions, explaining the principles he believes are important for disciplined portfolio management.

In this episode, Martin discusses why he believes certain recent market declines should not necessarily be viewed as buying opportunities. He also shares his perspective on SpaceX, comments on HIMS and its peptide-related business, revisits his bearish thesis on Intel, and analyzes SanDisk and Vertex, examining each company's business, valuation, competitive position, and the factors he believes could influence their future performance.

In this episode, Martin discusses why he believes Tesla may continue to face downside pressure and examines Oracle, explaining why he views the stock as potentially oversold. He also shares his perspective on SPRB, Broadcom, and Google, analyzing each company's business, valuation, competitive position, and the factors he believes could influence their future performance.

In this episode, Martin debates the science and use of peptides, discussing their potential applications, limitations, and the evidence supporting various claims. Throughout the conversation, he responds to opposing viewpoints, critiques common arguments, and explains the reasoning behind his perspective on peptide research, biomedical science, and related topics.

In this episode, Martin discusses his expectations for Google's upcoming performance and shares his outlook on the company's future prospects. He also analyzes Cerebras and Sionna (SION), examining their businesses, valuations, and potential growth opportunities. In addition, he discusses Quhuo (QH), outlining his concerns about the company and explaining the factors that shape his investment outlook.